Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000562887> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W2000562887 endingPage "317" @default.
- W2000562887 startingPage "313" @default.
- W2000562887 abstract "This study explores if advanced NSCLC patients with ECOG PS 2 and age<or=65 years can benefit from weekly docetaxel+carboplatin, with acceptable toxicities. Fifty-nine eligible patients with Stage IIIB (effusion) or Stage IV NSCLC were registered. Patients received docetaxel 35mg/m(2) and carboplatin AUC=2 on Days 1, 8, and 15 every 28-day cycle (maximum 8 cycles). Endpoints were 1-year survival, tumor response, PFS, and safety. Among the 59 eligible patients, the 1-year survival was 28% and median survival was 6 months (range: 1-24.3). The median duration of response for CR+PR was 5.4 months (range: 2.3-9.7), 1-year progression-free survival was 14% (median of 3.7 months, range<1-22.8). Patients received a median of 3 cycles (range: 1-9); 14 patients (24%) had toxicity-related reductions. Responses were: 1 CR (2%), 5 PR (10%), 22 SD (45%), and 21 PD (43%). Forty-nine patients were evaluable for response; 10 patients were non-evaluable due to: radiotherapy (1), withdrew consent (3), insurance issues (1), and early toxicity (1 each; dyspnea, weakness, and rash), and other illness (2). Fifty-eight patients were evaluable for safety. The primary Grade 3 or 4 toxicities were neutropenia and fatigue (10% each), nausea (9%), dehydration (7%), and vomiting (5%). A 12% response rate (plus 45% SD) confirms the relatively poor outcome of patients with advanced NSCLC who are PS 2. Toxicities of docetaxel+carboplatin are comparable to other regimens and this combination may provide an alternative for this group of patients. Further studies correlating patient characteristics with response are necessary." @default.
- W2000562887 created "2016-06-24" @default.
- W2000562887 creator A5028916394 @default.
- W2000562887 creator A5051272542 @default.
- W2000562887 creator A5053161145 @default.
- W2000562887 creator A5068051080 @default.
- W2000562887 creator A5075679795 @default.
- W2000562887 creator A5082949228 @default.
- W2000562887 creator A5085156317 @default.
- W2000562887 creator A5088800943 @default.
- W2000562887 date "2006-06-01" @default.
- W2000562887 modified "2023-09-25" @default.
- W2000562887 title "Results of a Phase II study of weekly docetaxel and carboplatin in Stage IIIB (with effusion) or Stage IV non-small cell lung cancer patients age ≤65 and performance status 2" @default.
- W2000562887 cites W1917502393 @default.
- W2000562887 cites W1979300931 @default.
- W2000562887 cites W1990667186 @default.
- W2000562887 cites W2003601931 @default.
- W2000562887 cites W2036475994 @default.
- W2000562887 cites W2127101185 @default.
- W2000562887 cites W2127405377 @default.
- W2000562887 cites W2128746268 @default.
- W2000562887 cites W2139248078 @default.
- W2000562887 cites W2170178407 @default.
- W2000562887 cites W2282886079 @default.
- W2000562887 cites W2411184490 @default.
- W2000562887 cites W2418768616 @default.
- W2000562887 cites W2504684570 @default.
- W2000562887 cites W2806177456 @default.
- W2000562887 doi "https://doi.org/10.1016/j.lungcan.2006.01.001" @default.
- W2000562887 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16621129" @default.
- W2000562887 hasPublicationYear "2006" @default.
- W2000562887 type Work @default.
- W2000562887 sameAs 2000562887 @default.
- W2000562887 citedByCount "2" @default.
- W2000562887 countsByYear W20005628872013 @default.
- W2000562887 crossrefType "journal-article" @default.
- W2000562887 hasAuthorship W2000562887A5028916394 @default.
- W2000562887 hasAuthorship W2000562887A5051272542 @default.
- W2000562887 hasAuthorship W2000562887A5053161145 @default.
- W2000562887 hasAuthorship W2000562887A5068051080 @default.
- W2000562887 hasAuthorship W2000562887A5075679795 @default.
- W2000562887 hasAuthorship W2000562887A5082949228 @default.
- W2000562887 hasAuthorship W2000562887A5085156317 @default.
- W2000562887 hasAuthorship W2000562887A5088800943 @default.
- W2000562887 hasConcept C126322002 @default.
- W2000562887 hasConcept C141071460 @default.
- W2000562887 hasConcept C2776256026 @default.
- W2000562887 hasConcept C2776694085 @default.
- W2000562887 hasConcept C2776907518 @default.
- W2000562887 hasConcept C2777063308 @default.
- W2000562887 hasConcept C2778239845 @default.
- W2000562887 hasConcept C2778570526 @default.
- W2000562887 hasConcept C2780580376 @default.
- W2000562887 hasConcept C2781190966 @default.
- W2000562887 hasConcept C2781451048 @default.
- W2000562887 hasConcept C71924100 @default.
- W2000562887 hasConcept C90924648 @default.
- W2000562887 hasConceptScore W2000562887C126322002 @default.
- W2000562887 hasConceptScore W2000562887C141071460 @default.
- W2000562887 hasConceptScore W2000562887C2776256026 @default.
- W2000562887 hasConceptScore W2000562887C2776694085 @default.
- W2000562887 hasConceptScore W2000562887C2776907518 @default.
- W2000562887 hasConceptScore W2000562887C2777063308 @default.
- W2000562887 hasConceptScore W2000562887C2778239845 @default.
- W2000562887 hasConceptScore W2000562887C2778570526 @default.
- W2000562887 hasConceptScore W2000562887C2780580376 @default.
- W2000562887 hasConceptScore W2000562887C2781190966 @default.
- W2000562887 hasConceptScore W2000562887C2781451048 @default.
- W2000562887 hasConceptScore W2000562887C71924100 @default.
- W2000562887 hasConceptScore W2000562887C90924648 @default.
- W2000562887 hasIssue "3" @default.
- W2000562887 hasLocation W20005628871 @default.
- W2000562887 hasLocation W20005628872 @default.
- W2000562887 hasOpenAccess W2000562887 @default.
- W2000562887 hasPrimaryLocation W20005628871 @default.
- W2000562887 hasRelatedWork W2013653877 @default.
- W2000562887 hasRelatedWork W2036842629 @default.
- W2000562887 hasRelatedWork W2050222620 @default.
- W2000562887 hasRelatedWork W2098455424 @default.
- W2000562887 hasRelatedWork W2102762868 @default.
- W2000562887 hasRelatedWork W2121726979 @default.
- W2000562887 hasRelatedWork W2125687910 @default.
- W2000562887 hasRelatedWork W2392023396 @default.
- W2000562887 hasRelatedWork W2468188714 @default.
- W2000562887 hasRelatedWork W2999074841 @default.
- W2000562887 hasVolume "52" @default.
- W2000562887 isParatext "false" @default.
- W2000562887 isRetracted "false" @default.
- W2000562887 magId "2000562887" @default.
- W2000562887 workType "article" @default.